New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States

Questions? Call 800-624-6242

About | Ordering | New

LoginRegister

| Items in cart [0]

The National Academies Press

Rights & Permissions

Free PDF Access

Sign in to download PDF book and chapters

Free Resources

Related Titles

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager Export the bibliographic data for this book in your chosen format
Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web.
Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book.
Reference Finder Paste in your own text to find books that relate to your topic.

Citation Manager

. "9. Findings, Conclusions, and Recommendations." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

Page
148


E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

This page intentionally left blank.

Page
148

Front Matter (R1-R14)

1. Summary (1-16)

2. Priority Setting for Health Related Investments: A Review of Methods (17-27)

3. Overview of the Analytic Approach (28-38)

4. Comparison of Disease Burdens and Costs (39-58)

5. Predictions on Vaccine Development (59-66)

6. Assessing the Likely Utilization of New Vaccines (67-91)

7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)

8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)

9. Findings, Conclusions, and Recommendations (127-148)

Appendix A: Some Examples of the Application of Project Selection Method (149-152)

Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)

Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)

Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)

Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)

Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)

Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)

Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)

Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)

Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)

Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)

Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)

Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)

Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)

Appendix O: Prospects for Immunizing Against Rotavirus (410-423)

Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)

Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)

Appendix R: Technical Notes (444-444)

Appendix S: Biographical Notes on Committee Members (445-449)

Appendix T: Additional Sources of Advice to the Committee (450-452)

Index (453-458)